{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:42:09Z","timestamp":1785786129548,"version":"3.56.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:00:00Z","timestamp":1404259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sports Med"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40279-014-0217-3","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T07:19:07Z","timestamp":1404285547000},"page":"1361-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Vaccination in Elite Athletes"],"prefix":"10.1007","volume":"44","author":[{"given":"Barbara C.","family":"G\u00e4rtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,2]]},"reference":[{"key":"217_CR1","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2012 global summary 2013. http:\/\/www.who.int\/immunization_monitoring\/data\/data_subject\/en\/index.html . Accessed 1 Jun 2013."},{"key":"217_CR2","unstructured":"St\u00e4ndige Impfkommission (STIKO). Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Epi Bull. 2012;283\u201310."},{"key":"217_CR3","unstructured":"European Center for Disease Prevention and Control. Vaccination schedules; 2013. http:\/\/www.euvac.net\/graphics\/euvac\/background.html . Accessed 1 Jun 2013."},{"key":"217_CR4","first-page":"1","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. General recommendations on immunization\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1\u201364.","journal-title":"MMWR Recomm Rep"},{"key":"217_CR5","unstructured":"Australian Government Department of Health and Aging. The Australian immunisation handbook. 10th ed; 2013."},{"key":"217_CR6","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1016\/j.vaccine.2013.08.008","volume":"31","author":"S Black","year":"2013","unstructured":"Black S. The role of health economic analyses in vaccine decision making. Vaccine. 2013;31:6046\u20139.","journal-title":"Vaccine"},{"key":"217_CR7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00019053-200523090-00001","volume":"23","author":"R Welte","year":"2005","unstructured":"Welte R, Trotter CL, Edmunds WJ, et al. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics. 2005;23:855\u201374.","journal-title":"Pharmacoeconomics"},{"key":"217_CR8","first-page":"387","volume":"67","author":"C Signorelli","year":"2011","unstructured":"Signorelli C, Gozzini A. Raccomandazioni Vaccinali per gli atleti professionisti. Guidelines for immunization practices in professional athletes. Ig Sanita Pubbl. 2011;67:387\u2013400.","journal-title":"Ig Sanita Pubbl"},{"key":"217_CR9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.131.6.1121","volume":"131","author":"BG Gatmaitan","year":"1970","unstructured":"Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the virulence of murine coxsackie-virus B-3 myocardiopathy by exercise. J Exp Med. 1970;131:1121\u201336.","journal-title":"J Exp Med"},{"key":"217_CR10","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/0002-8703(89)90409-2","volume":"117","author":"NG Ilback","year":"1989","unstructured":"Ilback NG, Fohlman J, Friman G. Exercise in coxsackie B3 myocarditis: effects on heart lymphocyte subpopulations and the inflammatory reaction. Am Heart J. 1989;117:1298\u2013302.","journal-title":"Am Heart J"},{"key":"217_CR11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF00144836","volume":"5","author":"RJ Kiel","year":"1989","unstructured":"Kiel RJ, Smith FE, Chason J, et al. Coxsackievirus B3 myocarditis in C3H\/HeJ mice: description of an inbred model and the effect of exercise on virulence. Eur J Epidemiol. 1989;5:348\u201350.","journal-title":"Eur J Epidemiol"},{"key":"217_CR12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JSM.0b013e31820758dc","volume":"21","author":"P Daly","year":"2011","unstructured":"Daly P, Gustafson R. Public health recommendations for athletes attending sporting events. Clin J Sport Med. 2011;21:67\u201370.","journal-title":"Clin J Sport Med"},{"key":"217_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00007256-199724010-00001","volume":"24","author":"EE Mast","year":"1997","unstructured":"Mast EE, Goodman RA. Prevention of infectious disease transmission in sports. Sports Med. 1997;24:1\u20137.","journal-title":"Sports Med"},{"key":"217_CR14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/infdis\/jis773","volume":"207","author":"WE Bischoff","year":"2013","unstructured":"Bischoff WE, Swett K, Leng I, et al. Exposure to influenza virus aerosols during routine patient care. J Infect Dis. 2013;207:1037\u201346.","journal-title":"J Infect Dis"},{"key":"217_CR15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0140-6736(90)92996-U","volume":"336","author":"NA Menkhaus","year":"1990","unstructured":"Menkhaus NA, Lanphear B, Linnemann CC. Airborne transmission of varicella-zoster virus in hospitals. Lancet. 1990;336:1315.","journal-title":"Lancet"},{"key":"217_CR16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/bjsm.2004.011643","volume":"38","author":"R Kordi","year":"2004","unstructured":"Kordi R, Wallace WA. Blood borne infections in sport: risks of transmission, methods of prevention, and recommendations for hepatitis B vaccination. Br J Sports Med. 2004;38:678\u201384.","journal-title":"Br J Sports Med"},{"key":"217_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.csm.2007.04.010","volume":"26","author":"JJ Pirozzolo","year":"2007","unstructured":"Pirozzolo JJ, LeMay DC. Blood-borne infections. Clin Sports Med. 2007;26:425\u201331.","journal-title":"Clin Sports Med"},{"key":"217_CR18","unstructured":"Pretot J. Mumps epidemic forces French to postpone games; 2011. http:\/\/www.moneycontrol.com\/news\/wire-news\/mumps-epidemic-forces-french-to-postpone-games_608077.html . Accessed 1 Jun 2013."},{"key":"217_CR19","unstructured":"Mentzer D, Keller-Stanislawski B. Daten zur Pharmakovigilanz von Impfstoffen aus dem Jahr 2011. Bulletin zur Arzneimittelsicherheit; 2013. http:\/\/www.pei.de\/SharedDocs\/Downloads\/bulletin-einzelartikel\/2013-daten-pharmakovigilanz-impfstoffe-2011.pdf?__blob=publicationFile&v=3 . Accessed 1 May 2014."},{"key":"217_CR20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1177\/009127000004001111","volume":"40","author":"A Vilella","year":"2000","unstructured":"Vilella A, Dal-Re R, Simo D, et al. Reactogenicity profile of tetanus\u2013diphtheria (adult-type) vaccine: results of a naturalistic study performed at an adult vaccination center. J Clin Pharmacol. 2000;40:1267\u201373.","journal-title":"J Clin Pharmacol"},{"key":"217_CR21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1045-1870(03)00033-5","volume":"14","author":"MB Rennels","year":"2003","unstructured":"Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria\u2013tetanus\u2013acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14:196\u20138.","journal-title":"Semin Pediatr Infect Dis"},{"key":"217_CR22","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2008.10.006","volume":"26","author":"J Gidudu","year":"2008","unstructured":"Gidudu J, Kohl KS, Halperin S, et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2008;26:6800\u201313.","journal-title":"Vaccine"},{"key":"217_CR23","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1016\/j.vaccine.2012.03.085","volume":"30","author":"JF Gidudu","year":"2012","unstructured":"Gidudu JF, Walco GA, Taddio A, et al. Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2012;30:4558\u201377.","journal-title":"Vaccine"},{"key":"217_CR24","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1016\/j.vaccine.2007.04.062","volume":"25","author":"KS Kohl","year":"2007","unstructured":"Kohl KS, Walop W, Gidudu J, et al. Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5839\u201357.","journal-title":"Vaccine"},{"key":"217_CR25","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1016\/j.vaccine.2007.04.056","volume":"25","author":"KS Kohl","year":"2007","unstructured":"Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 2007;25:5858\u201374.","journal-title":"Vaccine"},{"key":"217_CR26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cod.12053","volume":"68","author":"A Gente Lidholm","year":"2013","unstructured":"Gente Lidholm A, Bergfors E, Inerot A, et al. Unexpected loss of contact allergy to aluminium induced by vaccine. Contact Dermatitis. 2013;68:286\u201392.","journal-title":"Contact Dermatitis"},{"key":"217_CR27","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1016\/j.vaccine.2011.06.010","volume":"29","author":"RW Frenck Jr","year":"2011","unstructured":"Frenck RW Jr, Belshe R, Brady RC, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine. 2011;29:5666\u201374.","journal-title":"Vaccine"},{"key":"217_CR28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/irv.12000","volume":"7","author":"F Marra","year":"2013","unstructured":"Marra F, Young F, Richardson K, et al. A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses. 2013;7:584\u2013603.","journal-title":"Influenza Other Respir Viruses"},{"key":"217_CR29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.282.2.137","volume":"282","author":"KL Nichol","year":"1999","unstructured":"Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999;282:137\u201344.","journal-title":"JAMA"},{"key":"217_CR30","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1128\/JVI.02388-08","volume":"83","author":"S Sanden van der","year":"2009","unstructured":"van der Sanden S, Pallansch MA, van de Kassteele J, et al. Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine. J Virol. 2009;83:8693\u2013704.","journal-title":"J Virol"},{"key":"217_CR31","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1056\/NEJMoa0910074","volume":"362","author":"HE Jenkins","year":"2010","unstructured":"Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med. 2010;362:2360\u20139.","journal-title":"N Engl J Med"},{"key":"217_CR32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/14760584.5.5.669","volume":"5","author":"MM Venkatesan","year":"2006","unstructured":"Venkatesan MM, Ranallo RT. Live-attenuated Shigella vaccines. Expert Rev Vaccines. 2006;5:669\u201386.","journal-title":"Expert Rev Vaccines"},{"key":"217_CR33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/422454","volume":"39","author":"KS Kohl","year":"2004","unstructured":"Kohl KS, Marcy SM, Blum M, et al. Fever after immunization: current concepts and improved future scientific understanding. Clin Infect Dis. 2004;39:389\u201394.","journal-title":"Clin Infect Dis"},{"key":"217_CR34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.vaccine.2003.09.007","volume":"22","author":"S Michael Marcy","year":"2004","unstructured":"Michael Marcy S, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine. 2004;22:551\u20136.","journal-title":"Vaccine"},{"key":"217_CR35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/14760584.4.3.419","volume":"4","author":"T Tapiainen","year":"2005","unstructured":"Tapiainen T, Heininger U. Fever following immunization. Expert Rev Vaccines. 2005;4:419\u201327.","journal-title":"Expert Rev Vaccines"},{"key":"217_CR36","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1016\/j.vaccine.2011.08.076","volume":"29","author":"NJ Andrews","year":"2011","unstructured":"Andrews NJ, Walker WT, Finn A, et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine. 2011;29:7913\u20139.","journal-title":"Vaccine"},{"key":"217_CR37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","volume":"374","author":"R Prymula","year":"2009","unstructured":"Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374:1339\u201350.","journal-title":"Lancet"},{"key":"217_CR38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/hv.2.5.3220","volume":"2","author":"P Reinert","year":"2006","unstructured":"Reinert P, Fiquet A, Thomas S, et al. Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Hum Vaccin. 2006;2:215\u201321.","journal-title":"Hum Vaccin"},{"key":"217_CR39","first-page":"1","volume":"45","author":"Centers for Disease Control and Prevention","year":"1996","unstructured":"Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45:1\u201335.","journal-title":"MMWR Recomm Rep"},{"key":"217_CR40","unstructured":"Centers for Disease Control and Prevention. Possible Side-effects from Vaccines; 2014. http:\/\/www.cdc.gov\/vaccines\/vac-gen\/side-effects.htm . Accessed 1 May 2014"},{"key":"217_CR41","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","volume":"31","author":"NA Halsey","year":"2013","unstructured":"Halsey NA, Griffioen M, Dreskin SC, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine. 2013;31:6107\u201312.","journal-title":"Vaccine"},{"key":"217_CR42","first-page":"27","volume":"24","author":"RM D\u2019Souza","year":"2000","unstructured":"D\u2019Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell. 2000;24:27\u201333.","journal-title":"Commun Dis Intell"},{"key":"217_CR43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/08916930500144484","volume":"38","author":"DA Geier","year":"2005","unstructured":"Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38:295\u2013301.","journal-title":"Autoimmunity"},{"key":"217_CR44","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","volume":"166","author":"DN Juurlink","year":"2006","unstructured":"Juurlink DN, Stukel TA, Kwong J, et al. Guillain\u2013Barre syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166:2217\u201321.","journal-title":"Arch Intern Med"},{"key":"217_CR45","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","volume":"169","author":"J Stowe","year":"2009","unstructured":"Stowe J, Andrews N, Wise L, et al. Investigation of the temporal association of Guillain\u2013Barre syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169:382\u20138.","journal-title":"Am J Epidemiol"},{"key":"217_CR46","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00103-009-0961-y","volume":"52","author":"K Weisser","year":"2009","unstructured":"Weisser K, Barth I, Keller-Stanislawski B. Sicherheit von Impfstoffen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009;52:1053\u201364.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"217_CR47","first-page":"CD004407","volume":"2","author":"V Demicheli","year":"2012","unstructured":"Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;2:CD004407.","journal-title":"Cochrane Database Syst Rev"},{"key":"217_CR48","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1016\/S0264-410X(03)00271-8","volume":"21","author":"T Jefferson","year":"2003","unstructured":"Jefferson T, Price D, Demicheli V, et al. Unintended events following immunization with MMR: a systematic review. Vaccine. 2003;21:3954\u201360.","journal-title":"Vaccine"},{"key":"217_CR49","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00415-011-5984-2","volume":"258","author":"MF Farez","year":"2011","unstructured":"Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258:1197\u2013206.","journal-title":"J Neurol"},{"key":"217_CR50","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.vaccine.2013.01.054","volume":"31","author":"JG Breugelmans","year":"2013","unstructured":"Breugelmans JG, Lewis RF, Agbenu E, et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013;31:1819\u201329.","journal-title":"Vaccine"},{"key":"217_CR51","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1016\/j.vaccine.2010.06.056","volume":"28","author":"N Goulleret","year":"2010","unstructured":"Goulleret N, Mauvisseau E, Essevaz-Roulet M, et al. Safety profile of live varicella virus vaccine (Oka\/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine. 2010;28:5878\u201382.","journal-title":"Vaccine"},{"key":"217_CR52","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/0140-6736(93)91069-X","volume":"341","author":"E Miller","year":"1993","unstructured":"Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993;341:979\u201382.","journal-title":"Lancet"},{"key":"217_CR53","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1016\/j.vaccine.2006.06.049","volume":"24","author":"MC Bonnet","year":"2006","unstructured":"Bonnet MC, Dutta A, Weinberger C, et al. Mumps vaccine virus strains and aseptic meningitis. Vaccine. 2006;24:7037\u201345.","journal-title":"Vaccine"},{"key":"217_CR54","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/01.inf.0000177282.53500.77","volume":"24","author":"LP Celentano","year":"2005","unstructured":"Celentano LP, Massari M, Paramatti D, et al. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24:761\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"217_CR55","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa050824","volume":"353","author":"JI Ward","year":"2005","unstructured":"Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555\u201363.","journal-title":"N Engl J Med"},{"key":"217_CR56","doi-asserted-by":"crossref","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","volume":"131","author":"NP Klein","year":"2013","unstructured":"Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131:e1716\u201322.","journal-title":"Pediatrics"},{"key":"217_CR57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.inf.0000202082.56403.c4","volume":"25","author":"SA Halperin","year":"2006","unstructured":"Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus\u2013diphtheria vaccination can one give adult formulation tetanus\u2013diphtheria\u2013acellular pertussis vaccine? Pediatr Infect Dis J. 2006;25:195\u2013200.","journal-title":"Pediatr Infect Dis J"},{"key":"217_CR58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4161\/hv.5.5.6911","volume":"5","author":"J Beytout","year":"2009","unstructured":"Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin. 2009;5:315\u201321.","journal-title":"Hum Vaccin"},{"key":"217_CR59","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1016\/j.vaccine.2010.09.034","volume":"28","author":"EA Talbot","year":"2010","unstructured":"Talbot EA, Brown KH, Kirkland KB, et al. The safety of immunizing with tetanus\u2013diphtheria\u2013acellular pertussis vaccine (Tdap) less than 2\u00a0years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010;28:8001\u20137.","journal-title":"Vaccine"},{"key":"217_CR60","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/hv.19917","volume":"8","author":"L Manzoli","year":"2012","unstructured":"Manzoli L, Ioannidis JP, Flacco ME, et al. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother. 2012;8:851\u201362.","journal-title":"Hum Vaccin Immunother"},{"key":"217_CR61","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1016\/j.vaccine.2011.08.011","volume":"29","author":"T Heikkinen","year":"2011","unstructured":"Heikkinen T, Heinonen S. Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine. 2011;29:7529\u201334.","journal-title":"Vaccine"},{"key":"217_CR62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2334-13-224","volume":"13","author":"JI Beran","year":"2013","unstructured":"Beran JI, Peeters M, Dewe W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis. 2013;13:224.","journal-title":"BMC Infect Dis"},{"key":"217_CR63","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.vaccine.2012.11.074","volume":"31","author":"DP Greenberg","year":"2013","unstructured":"Greenberg DP, Robertson CA, Noss MJ, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770\u20136.","journal-title":"Vaccine"},{"key":"217_CR64","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1586\/erv.12.108","volume":"11","author":"SL Toback","year":"2012","unstructured":"Toback SL, Levin MJ, Block SL, et al. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines. 2012;11:1293\u2013303.","journal-title":"Expert Rev Vaccines"},{"key":"217_CR65","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1016\/j.vaccine.2011.09.109","volume":"29","author":"SL Block","year":"2011","unstructured":"Block SL, Yi T, Sheldon E, et al. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine. 2011;29:9391\u20137.","journal-title":"Vaccine"},{"key":"217_CR66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","volume":"6","author":"DT O\u2019Hagan","year":"2007","unstructured":"O\u2019Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6:699\u2013710.","journal-title":"Expert Rev Vaccines"},{"key":"217_CR67","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1128\/CVI.05111-11","volume":"18","author":"HJ Cheong","year":"2011","unstructured":"Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of the influenza A\/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol. 2011;18:1358\u201364.","journal-title":"Clin Vaccine Immunol"},{"key":"217_CR68","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2011.12.098","volume":"30","author":"C Reed","year":"2012","unstructured":"Reed C, Meltzer MI, Finelli L, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993\u20138.","journal-title":"Vaccine"},{"key":"217_CR69","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1016\/j.vaccine.2011.09.077","volume":"29","author":"F Young","year":"2011","unstructured":"Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine. 2011;29:8788\u2013801.","journal-title":"Vaccine"},{"key":"217_CR70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2012.10.084","volume":"31","author":"CA DiazGranados","year":"2012","unstructured":"DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49\u201357.","journal-title":"Vaccine"},{"key":"217_CR71","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/01.inf.0000220229.51531.47","volume":"25","author":"T Vesikari","year":"2006","unstructured":"Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J. 2006;25:590\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"217_CR72","doi-asserted-by":"crossref","unstructured":"Frank C, Walter J, Muehlen M, et al. Large outbreak of hepatitis A in tourists staying at a hotel in Hurghada, Egypt, 2004: orange juice implicated. Euro Surveill. 2005;10(6):E050609.2.","DOI":"10.2807\/esw.10.23.02720-en"},{"key":"217_CR73","doi-asserted-by":"crossref","unstructured":"Gillesberg Lassen S, Soborg B, Midgley S, et al. Ongoing multi-strain food-borne hepatitis A outbreak with frozen berries as suspected vehicle: four Nordic countries affected, October 2012 to April 2013. Euro Surveill. 2013;18(7):20467.","DOI":"10.2807\/ese.18.17.20467-en"},{"key":"217_CR74","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1002\/hep.21052","volume":"43","author":"A Martin","year":"2006","unstructured":"Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology. 2006;43:S164\u201372.","journal-title":"Hepatology"},{"key":"217_CR75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pedhc.2006.12.011","volume":"22","author":"MB Koslap-Petraco","year":"2008","unstructured":"Koslap-Petraco MB, Shub M, Judelsohn R. Hepatitis A, disease burden and current childhood vaccination strategies in the United States. J Pediatr Health Care. 2008;22:3\u201311.","journal-title":"J Pediatr Health Care"},{"key":"217_CR76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.medmal.2012.10.002","volume":"42","author":"A Grosset-Janin","year":"2012","unstructured":"Grosset-Janin A, Nicolas X, Saraux A. Sport and infectious risk: a systematic review of the literature over 20\u00a0years. Med Mal Infect. 2012;42:533\u201344.","journal-title":"Med Mal Infect"},{"key":"217_CR77","first-page":"328","volume":"3","author":"R Raz","year":"2001","unstructured":"Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Isr Med Assoc J. 2001;3:328\u201332.","journal-title":"Isr Med Assoc J"},{"key":"217_CR78","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","volume":"68","author":"NK Tong","year":"2005","unstructured":"Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68:2298\u2013303.","journal-title":"Kidney Int"},{"key":"217_CR79","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1016\/j.vaccine.2012.08.074","volume":"30","author":"CJ Hoebe","year":"2012","unstructured":"Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix(R) or HBVaxPro(R) results in better response rates than does revaccination with three doses of Engerix-B(R) in previous non-responders. Vaccine. 2012;30:6734\u20137.","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"217_CR80","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1055\/s-2007-971991","volume":"19","author":"DB Pyne","year":"1998","unstructured":"Pyne DB, Gleeson M. Effects of intensive exercise training on immunity in athletes. Int J Sports Med. 1998;19(Suppl 3):S183\u201391.","journal-title":"Int J Sports Med"},{"key":"217_CR81","doi-asserted-by":"crossref","first-page":"O242","DOI":"10.1111\/1469-0691.12384","volume":"20","author":"M Caseris","year":"2014","unstructured":"Caseris M, Houhou N, Longuet P, et al. French 2010\u20132011 measles outbreak in adults: report from a Parisian teaching hospital. Clin Microbiol Infect. 2014;20:O242\u20134.","journal-title":"Clin Microbiol Infect"},{"key":"217_CR82","doi-asserted-by":"crossref","first-page":"e68909","DOI":"10.1371\/journal.pone.0068909","volume":"8","author":"K Schonberger","year":"2013","unstructured":"Schonberger K, Ludwig MS, Wildner M, et al. Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009: a risk estimation. PLoS ONE. 2013;8:e68909.","journal-title":"PLoS ONE"},{"key":"217_CR83","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/heapol\/15.4.408","volume":"15","author":"W Edmunds","year":"2000","unstructured":"Edmunds W, Dejene A, Mekonnen Y, et al. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plan. 2000;15:408\u201316.","journal-title":"Health Policy Plan"},{"key":"217_CR84","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S0950268800004672","volume":"125","author":"WJ Edmunds","year":"2000","unstructured":"Edmunds WJ, Gay NJ, Kretzschmar M, et al. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect. 2000;125:635\u201350.","journal-title":"Epidemiol Infect"},{"key":"217_CR85","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1202865","volume":"367","author":"AE Barskey","year":"2012","unstructured":"Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in orthodox Jewish communities in the United States. N Engl J Med. 2012;367:1704\u201313.","journal-title":"N Engl J Med"},{"key":"217_CR86","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(08)60419-5","volume":"371","author":"A Hviid","year":"2008","unstructured":"Hviid A, Rubin S, Muhlemann K. Mumps. Lancet. 2008;371:932\u201344.","journal-title":"Lancet"},{"key":"217_CR87","unstructured":"Owen P. Mumps outbreak puts hockey game on ice; 2007. http:\/\/peel.library.ualberta.ca\/newspapers\/GAT\/2007\/11\/29\/17\/Img\/Pg017.pdf . Accessed 19 Dec 2013."},{"key":"217_CR88","unstructured":"Telegraph T. Biarritz squad quarantined over mumps scare following Amlin Challenge Cup win over Gloucester. 2013. http:\/\/www.telegraph.co.uk\/sport\/rugbyunion\/club\/9975206\/Biarritz-squad-quarantined-over-mumps-scare-following-Amlin-Challenge-Cup-win-over-Gloucester.html . Accessed 19 Dec 2013."},{"key":"217_CR89","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/JVI.06125-11","volume":"86","author":"SA Rubin","year":"2012","unstructured":"Rubin SA, Link MA, Sauder CJ, et al. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86:615\u201320.","journal-title":"J Virol"},{"key":"217_CR90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2334-12-140","volume":"12","author":"GG Rijckevorsel van","year":"2012","unstructured":"van Rijckevorsel GG, Damen M, Sonder GJ, et al. Seroprevalence of varicella-zoster virus and predictors for seronegativity in the Amsterdam adult population. BMC Infect Dis. 2012;12:140.","journal-title":"BMC Infect Dis"},{"key":"217_CR91","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mbs.2008.12.009","volume":"218","author":"B Ogunjimi","year":"2009","unstructured":"Ogunjimi B, Hens N, Goeyvaerts N, et al. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. Math Biosci. 2009;218:80\u20137.","journal-title":"Math Biosci"},{"key":"217_CR92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10096-010-1106-9","volume":"30","author":"D Hervas","year":"2011","unstructured":"Hervas D, Henales V, Yeste S, et al. How frequent is varicella-associated pneumonia in children? Eur J Clin Microbiol Infect Dis. 2011;30:435\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"217_CR93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/00365549609049061","volume":"28","author":"A Nilsson","year":"1996","unstructured":"Nilsson A, Ortqvist A. Severe varicella pneumonia in adults in Stockholm County 1980\u20131989. Scand J Infect Dis. 1996;28:121\u20133.","journal-title":"Scand J Infect Dis"},{"key":"217_CR94","unstructured":"Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. The pink book: course textbook. 12th ed.; 2012."},{"key":"217_CR95","unstructured":"World Health Organization. Yellow fever; 2015. http:\/\/www.who.int\/topics\/yellow_fever\/en\/ . Accessed 1 May 2014."},{"key":"217_CR96","doi-asserted-by":"crossref","unstructured":"Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766\u201374, 774A\u201374E.","DOI":"10.2471\/BLT.10.085233"},{"key":"217_CR97","unstructured":"World Health Organization. Vaccines and biologicals: tick-borne encephalitis; 2014. http:\/\/www.who.int\/immunization\/topics\/tick_encephalitis\/en\/ . Accessed 1 May 2014."},{"key":"217_CR98","unstructured":"World Health Organization. Poliomyelitis; 2014. http:\/\/www.who.int\/topics\/poliomyelitis\/en\/ . Accessed 1 May 2014."},{"key":"217_CR99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.7883\/yoken.JJID.2009.51","volume":"62","author":"T Sugawara","year":"2009","unstructured":"Sugawara T, Ohsuka Y, Taya K, et al. Diarrhea as a minor adverse effect due to oral polio vaccine. Jpn J Infect Dis. 2009;62:51\u20133.","journal-title":"Jpn J Infect Dis"},{"key":"217_CR100","unstructured":"World Health Organization. Typhoid fever; 2014. http:\/\/www.who.int\/topics\/typhoid_fever\/en\/ . Accessed 1 May 2014."},{"key":"217_CR101","first-page":"CD001261","volume":"1","author":"E Anwar","year":"2014","unstructured":"Anwar E, Goldberg E, Fraser A, et al. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2014;1:CD001261.","journal-title":"Cochrane Database Syst Rev"},{"key":"217_CR102","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/QCO.0b013e328356ffeb","volume":"25","author":"LB Martin","year":"2012","unstructured":"Martin LB. Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect Dis. 2012;25:489\u201399.","journal-title":"Curr Opin Infect Dis"},{"key":"217_CR103","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1086\/381548","volume":"38","author":"EM Begier","year":"2004","unstructured":"Begier EM, Burwen DR, Haber P, et al. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis. 2004;38:771\u20139.","journal-title":"Clin Infect Dis"},{"key":"217_CR104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1708-8305.1998.tb00449.x","volume":"5","author":"SJ Cryz Jr","year":"1998","unstructured":"Cryz SJ Jr. Patient compliance in the use of Vivotif Berna(R) vaccine, typhoid vaccine, live oral Ty21a. J Travel Med. 1998;5:14\u20137.","journal-title":"J Travel Med"},{"key":"217_CR105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJM199206043262317","volume":"326","author":"ED Barnett","year":"1992","unstructured":"Barnett ED, Klein JO, Teele DW. Pneumococcal vaccine for Olympic athletes and visitors to Spain. N Engl J Med. 1992;326:1572.","journal-title":"N Engl J Med"},{"key":"217_CR106","first-page":"437","volume":"327","author":"A Plasencia","year":"1992","unstructured":"Plasencia A, Segura A, Farres J, et al. Pneumococcal vaccine for Olympic athletes and visitors to Spain. Barcelona Olympic Organizing Committee. N Engl J Med. 1992;327:437.","journal-title":"N Engl J Med"},{"key":"217_CR107","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s40265-013-0079-2","volume":"73","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs. 2013;73:1147\u201355.","journal-title":"Drugs"},{"key":"217_CR108","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1\u201328.","journal-title":"MMWR Recomm Rep"},{"key":"217_CR109","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/hv.27739","volume":"10","author":"YC Zahlanie","year":"2014","unstructured":"Zahlanie YC, Hammadi MM, Ghanem ST, et al. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995\u20131007.","journal-title":"Hum Vaccin Immunother"},{"key":"217_CR110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","volume":"11","author":"RZ Jafri","year":"2013","unstructured":"Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:17.","journal-title":"Popul Health Metr"},{"issue":"Suppl 2","key":"217_CR111","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"27","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51\u201363.","journal-title":"Vaccine"},{"key":"217_CR112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-013-0029-2","volume":"27","author":"NJ Carter","year":"2013","unstructured":"Carter NJ. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero\u00ae): a review of its use in primary and booster vaccination. BioDrugs. 2013;27:263\u201374.","journal-title":"BioDrugs"},{"key":"217_CR113","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825\u201335.","journal-title":"Lancet"},{"key":"217_CR114","first-page":"816","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"217_CR115","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","volume":"31","author":"LA Jackson","year":"2013","unstructured":"Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50\u00a0years and older. Vaccine. 2013;31:3594\u2013602.","journal-title":"Vaccine"},{"key":"217_CR116","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.vaccine.2013.05.010","volume":"31","author":"LA Jackson","year":"2013","unstructured":"Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70\u00a0years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585\u201393.","journal-title":"Vaccine"},{"key":"217_CR117","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","volume":"31","author":"LA Jackson","year":"2013","unstructured":"Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31:3577\u201384.","journal-title":"Vaccine"},{"key":"217_CR118","first-page":"1","volume":"63","author":"EC Briere","year":"2014","unstructured":"Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1\u201314.","journal-title":"MMWR Recomm Rep"},{"key":"217_CR119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S0950268800048640","volume":"107","author":"JM Best","year":"1991","unstructured":"Best JM. Rubella vaccines: past, present and future. Epidemiol Infect. 1991;107:17\u201330.","journal-title":"Epidemiol Infect"},{"key":"217_CR120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.siny.2007.01.017","volume":"12","author":"JM Best","year":"2007","unstructured":"Best JM. Rubella. Semin Fetal Neonatal Med. 2007;12:182\u201392.","journal-title":"Semin Fetal Neonatal Med"},{"key":"217_CR121","doi-asserted-by":"crossref","unstructured":"Janta D, Stanescu A, Lupulescu E, et al. Ongoing rubella outbreak among adolescents in Salaj, Romania, September 2011\u2013January 2012. Euro Surveill. 2012;17(7):pii 20089.","DOI":"10.2807\/ese.17.07.20089-en"},{"key":"217_CR122","first-page":"724","volume":"19","author":"DA Geier","year":"2001","unstructured":"Geier DA, Geier MR. Rubella vaccine and arthritic adverse reactions: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database from 1991 through 1998. Clin Exp Rheumatol. 2001;19:724\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"217_CR123","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.1997.03550070043036","volume":"278","author":"P Ray","year":"1997","unstructured":"Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA. 1997;278:551\u20136.","journal-title":"JAMA"},{"key":"217_CR124","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(96)12031-6","volume":"349","author":"AJ Tingle","year":"1997","unstructured":"Tingle AJ, Mitchell LA, Grace M, et al. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet. 1997;349:1277\u201381.","journal-title":"Lancet"},{"key":"217_CR125","first-page":"630","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. FDA Licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"217_CR126","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","volume":"11","author":"B Lu","year":"2011","unstructured":"Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.","journal-title":"BMC Infect Dis"},{"key":"217_CR127","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","volume":"7","author":"MH Einstein","year":"2011","unstructured":"Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12\u201324 in a phase III randomized study of healthy women aged 18\u201345\u00a0years. Hum Vaccin. 2011;7:1343\u201358.","journal-title":"Hum Vaccin"},{"key":"217_CR128","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.4161\/hv.7.12.18282","volume":"7","author":"MH Einstein","year":"2011","unstructured":"Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16\/18 vaccine and the HPV-6\/11\/16\/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18\u201345\u00a0years. Hum Vaccin. 2011;7:1359\u201373.","journal-title":"Hum Vaccin"},{"key":"217_CR129","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.vaccine.2013.06.057","volume":"31","author":"SE Goldstone","year":"2013","unstructured":"Goldstone SE, Jessen H, Palefsky JM, et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine. 2013;31:3849\u201355.","journal-title":"Vaccine"},{"key":"217_CR130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2011.12.005","volume":"10","author":"MJ Warrell","year":"2012","unstructured":"Warrell MJ. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med Infect Dis. 2012;10:1\u201315.","journal-title":"Travel Med Infect Dis"},{"key":"217_CR131","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359\u00a0years. Clin Infect Dis. 2012;54:922\u20138.","journal-title":"Clin Infect Dis"},{"key":"217_CR132","unstructured":"Reuters. Hannover star contracts tuberculosis; 2013. http:\/\/asia.eurosport.com\/football\/bundesliga-1\/2012-2013\/hanover-96-s-franca-out-for-months-with-tuberculosis_sto3635224\/story.shtml . Accessed 1 June 2014."},{"key":"217_CR133","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1249\/00005768-199402000-00002","volume":"26","author":"DC Nieman","year":"1994","unstructured":"Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26:128\u201339.","journal-title":"Med Sci Sports Exerc"},{"key":"217_CR134","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-2007-1021281","volume":"13","author":"H Gabriel","year":"1992","unstructured":"Gabriel H, Schwarz L, Steffens G, et al. Immunoregulatory hormones, circulating leucocyte and lymphocyte subpopulations before and after endurance exercise of different intensities. Int J Sports Med. 1992;13:359\u201366.","journal-title":"Int J Sports Med"},{"key":"217_CR135","first-page":"316","volume":"30","author":"DC Nieman","year":"1990","unstructured":"Nieman DC, Johanssen LM, Lee JW, et al. Infectious episodes in runners before and after the Los Angeles Marathon. J Sports Med Phys Fitness. 1990;30:316\u201328.","journal-title":"J Sports Med Phys Fitness"},{"key":"217_CR136","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/bjsm.34.4.246","volume":"34","author":"BK Pedersen","year":"2000","unstructured":"Pedersen BK, Toft AD. Effects of exercise on lymphocytes and cytokines. Br J Sports Med. 2000;34:246\u201351.","journal-title":"Br J Sports Med"},{"key":"217_CR137","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1440-2440(99)80176-5","volume":"2","author":"BK Pedersen","year":"1999","unstructured":"Pedersen BK, Bruunsgaard H, Jensen M, et al. Exercise and the immune system: influence of nutrition and ageing. J Sci Med Sport. 1999;2:234\u201352.","journal-title":"J Sci Med Sport"},{"key":"217_CR138","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1016\/j.vaccine.2012.08.022","volume":"30","author":"KM Edwards","year":"2012","unstructured":"Edwards KM, Pung MA, Tomfohr LM, et al. Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of weaker and stronger immune response. Vaccine. 2012;30:6389\u201395.","journal-title":"Vaccine"},{"key":"217_CR139","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbi.2010.01.009","volume":"24","author":"KM Edwards","year":"2010","unstructured":"Edwards KM, Campbell JP, Ring C, et al. Exercise intensity does not influence the efficacy of eccentric exercise as a behavioural adjuvant to vaccination. Brain Behav Immun. 2010;24:623\u201330.","journal-title":"Brain Behav Immun"},{"key":"217_CR140","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bbi.2012.02.004","volume":"26","author":"JE Long","year":"2012","unstructured":"Long JE, Ring C, Drayson M, et al. Vaccination response following aerobic exercise: can a brisk walk enhance antibody response to pneumococcal and influenza vaccinations? Brain Behav Immun. 2012;26:680\u20137.","journal-title":"Brain Behav Immun"},{"key":"217_CR141","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1249\/MSS.0b013e3182a75ff2","volume":"46","author":"SM Ranadive","year":"2014","unstructured":"Ranadive SM, Cook M, Kappus RM, et al. Effect of acute aerobic exercise on vaccine efficacy in older adults. Med Sci Sports Exerc. 2014;46:455\u201361.","journal-title":"Med Sci Sports Exerc"},{"key":"217_CR142","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1016\/j.vaccine.2008.03.051","volume":"26","author":"I Rosic","year":"2008","unstructured":"Rosic I, Malicevic S, Medic S, et al. Immune response by athletes to hepatitis B vaccination. Vaccine. 2008;26:3190\u20131.","journal-title":"Vaccine"},{"key":"217_CR143","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbi.2009.10.001","volume":"24","author":"JP Campbell","year":"2010","unstructured":"Campbell JP, Edwards KM, Ring C, et al. The effects of vaccine timing on the efficacy of an acute eccentric exercise intervention on the immune response to an influenza vaccine in young adults. Brain Behav Immun. 2010;24:236\u201342.","journal-title":"Brain Behav Immun"},{"key":"217_CR144","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1016\/j.vaccine.2008.08.052","volume":"26","author":"H Petousis-Harris","year":"2008","unstructured":"Petousis-Harris H. Vaccine injection technique and reactogenicity: evidence for practice. Vaccine. 2008;26:6299\u2013304.","journal-title":"Vaccine"},{"key":"217_CR145","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/adc.2007.118695","volume":"92","author":"M Ipp","year":"2007","unstructured":"Ipp M, Taddio A, Sam J, et al. Vaccine-related pain: randomised controlled trial of two injection techniques. Arch Dis Child. 2007;92:1105\u20138.","journal-title":"Arch Dis Child"},{"key":"217_CR146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archpedi.1997.02170400041007","volume":"151","author":"MM Braun","year":"1997","unstructured":"Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med. 1997;151:255\u20139.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"217_CR147","first-page":"457","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. Syncope after vaccination\u2014United States, January 2005\u2013July 2007. MMWR Morb Mortal Wkly Rep. 2008;57:457\u201360.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"217_CR148","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.pcad.2012.02.003","volume":"54","author":"JL Hastings","year":"2012","unstructured":"Hastings JL, Levine BD. Syncope in the athletic patient. Prog Cardiovasc Dis. 2012;54:438\u201344.","journal-title":"Prog Cardiovasc Dis"},{"key":"217_CR149","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.02430-07","volume":"46","author":"D Huzly","year":"2008","unstructured":"Huzly D, Schenk T, Jilg W, et al. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol. 2008;46:1298\u2013306.","journal-title":"J Clin Microbiol"},{"key":"217_CR150","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CVI.00660-12","volume":"20","author":"JS Rota","year":"2013","unstructured":"Rota JS, Rosen JB, Doll MK, et al. Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York City in 2009. Clin Vaccine Immunol. 2013;20:391\u20136.","journal-title":"Clin Vaccine Immunol"},{"key":"217_CR151","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2008.09.012","volume":"26","author":"I Velicko","year":"2008","unstructured":"Velicko I, Muller LL, Pebody R, et al. Nationwide measles epidemic in Ukraine: the effect of low vaccine effectiveness. Vaccine. 2008;26:6980\u20135.","journal-title":"Vaccine"},{"key":"217_CR152","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.vaccine.2008.02.028","volume":"26","author":"AV Atrasheuskaya","year":"2008","unstructured":"Atrasheuskaya AV, Kulak MV, Neverov AA, et al. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000\u20132005. Vaccine. 2008;26:2111\u20138.","journal-title":"Vaccine"},{"key":"217_CR153","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcv.2004.11.024","volume":"34","author":"AV Atrasheuskaya","year":"2005","unstructured":"Atrasheuskaya AV, Blatun EM, Neverov AA, et al. Measles in Minsk, Belarus, 2001\u20132003: clinical, virological and serological parameters. J Clin Virol. 2005;34:179\u201385.","journal-title":"J Clin Virol"},{"key":"217_CR154","first-page":"147","volume":"14","author":"MK Hostetter","year":"1999","unstructured":"Hostetter MK. Infectious diseases in internationally adopted children: findings in children from China, Russia, and eastern Europe. Adv Pediatr Infect Dis. 1999;14:147\u201361.","journal-title":"Adv Pediatr Infect Dis"},{"key":"217_CR155","first-page":"485","volume":"22","author":"B Kriz","year":"1978","unstructured":"Kriz B, Burian V, Sladky K, et al. Comparison of titration results of diphtheric antitoxic antibodies obtained by means of Jensen\u2019s method and the methods of tissue cultures and haemagglutination. J Hyg Epidemiol Microbiol Immunol. 1978;22:485\u201393.","journal-title":"J Hyg Epidemiol Microbiol Immunol"}],"container-title":["Sports Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40279-014-0217-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40279-014-0217-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40279-014-0217-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T22:50:21Z","timestamp":1689375021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40279-014-0217-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,2]]},"references-count":155,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1007\/s40279-014-0217-3","relation":{},"ISSN":["0112-1642","1179-2035"],"issn-type":[{"value":"0112-1642","type":"print"},{"value":"1179-2035","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,2]]}}}